ResearcherRockefeller UniversityActive in the last 2 years

JEFFREY Victor RAVETCH

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2024-9041; OpenAlex author ID A5007474253; NIH RePORTER profile ID 1884719. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 grant

Papers 1

Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. Co-author DOI 10.1016/j.isci.2022.105317 ↗

Grants 1

Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer R01CA258324 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mikael Karlsson · 1 shared paper, 1 shared grant, 2022–2025 · strength 1.19
- Grant Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer R01CA258324 ↗
- Paper Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. DOI 10.1016/j.isci.2022.105317 ↗
Rainer Lothar Heuchel · 1 shared paper, 2022 · strength 0.12
- Paper Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. DOI 10.1016/j.isci.2022.105317 ↗
Dhifaf Sarhan · 1 shared paper, 2022 · strength 0.12
- Paper Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. DOI 10.1016/j.isci.2022.105317 ↗
Matthias J. Löhr · 1 shared paper, 2022 · strength 0.12
- Paper Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. DOI 10.1016/j.isci.2022.105317 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.